Understanding DLK1: Potential Drug Target and Biomarker for Various Diseases

Target Name: DLK1

NCBI ID: G8788

DLK1

Understanding DLK1: Potential Drug Target and Biomarker for Various Diseases

DLK1 (fetal antigen 1) is a protein that is expressed in various tissues and cells during fetal development. It is a member of the homeobox gene family, which is responsible for the development and maintenance of tissues and organs during embryonic development. DLK1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DLK1 is involved in the development and maintenance of many tissues during fetal development, including the brain, spinal cord, and heart. It is expressed in the neural spinal cord segments, which are the basic units of the nervous system that develop during fetal development. It is also expressed in the heart, where it plays a role in the development and maintenance of the heart muscle.

In addition to its role in fetal development, DLK1 has also been shown to play a role in the development and progression of various diseases. For example, studies have shown that high levels of DLK1 are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, high levels of DLK1 have been shown to be associated with the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

As a potential drug target, DLK1 has been studied for its potential therapeutic uses in a variety of settings. One approach is to target DLK1 directly with small molecules, such as drugs that can modulate its activity. This approach has been used to study the effects of various small molecules on DLK1-mediated signaling pathways, including the role of DLK1 in the development and progression of neurodegenerative diseases.

Another approach to targeting DLK1 is to use antibodies that can specifically recognize and target it. This approach has been used to study the effects of antibodies on DLK1-mediated signaling pathways, as well as their potential therapeutic uses in a variety of settings.

In addition to its potential therapeutic uses, DLK1 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that the levels of DLK1 are significantly elevated in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease. Additionally, studies have shown that the levels of DLK1 are elevated in the brains of individuals with Parkinson's disease, and that these levels are associated with the severity of the disease.

Overall, DLK1 is a protein that is involved in the development and maintenance of various tissues during fetal development, and has been shown to play a role in the development and progression of a variety of diseases. As a potential drug target and biomarker, DLK1 is a promising target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of DLK1 in fetal development and disease, and to develop effective therapies based on its unique properties.

Protein Name: Delta Like Non-canonical Notch Ligand 1

Functions: May have a role in neuroendocrine differentiation

The "DLK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets